Search hospitals > Missouri > Cape Girardeau
Southeast Cancer Center
Claim this profileCape Girardeau, Missouri 63703
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
317 reported clinical trials
2 medical researchers
Summary
Southeast Cancer Center is a medical facility located in Cape Girardeau, Missouri. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Southeast Cancer Center is involved with conducting 317 clinical trials across 450 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Bryan A. FallerCrossroads Cancer Center2 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
229 reported clinical trials
292 drugs studied
James L. WadeDecatur Memorial Hospital3 years of reported clinical research
Studies Recurrence
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Southeast Cancer Center
Breast Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Bladder Carcinoma
Prostate Cancer
Melanoma
Pancreatic Cancer
Cutaneous Melanoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Southeast Cancer Center?
Southeast Cancer Center is a medical facility located in Cape Girardeau, Missouri. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Southeast Cancer Center is involved with conducting 317 clinical trials across 450 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Southeast Cancer Center located?
**Mercy Hospital Southeast**
- **Address:** 1701 Lacey Street, Cape Girardeau, MO, 63701
- **Directions:** Accessible via US-61 N, follow signs for Cape Girardeau.
Who should I call to ask about financial aid or insurance network?
**Southeast Cancer Center Contact Information:**
- **Financial Assistance:** For details on financial assistance programs, price estimates, and cash payment discounts, contact Patient Financial Services at 334-793-8711 or 1-800-592-5384.
- **Insurance Inquiries:** Patients should contact their insurance provider to verify policy specifics and precertification requirements before scheduling services or procedures. For coverage details and financial obligations, please reach out to your insurance provider directly.
What insurance does Southeast Cancer Center accept?
The Southeast Cancer Center accepts a wide range of insurance plans, including but not limited to Aetna, Blue Cross Blue Shield, Cigna, Coventry, Medicaid, and UnitedHealthcare. It's important to verify coverage directly with your healthcare providers, as individual physicians may not participate in all plans. This ensures full understanding of insurance coverage for treatments provided.
What awards or recognition has Southeast Cancer Center received?
The Southeast Cancer Center, located in Cape Girardeau, Missouri, is renowned for its partnership with the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). This collaboration allows for multisite cancer clinical trials and studies across diverse populations, aiming to enhance patient outcomes and decrease cancer disparities. The center is also a recognized member of the Southeast Clinical Oncology Research Consortium NCORP, highlighting its significant contributions to cancer research.